Miron Derchansky

Miron is the Managing Director of Blackletter Group, a boutique life sciences consultancy helping senior executives find, assess and operationalize emerging science and nascent technologies at the intersection of digital and pharma. Prior to founding Blackletter, Miron was the VP of Innovation at LEO Pharma where he established digital health innovation labs in Toronto and Tel Aviv and co-headed LEO’s digital corporate VC arm. He acquired his passion for modernizing pharma while working at the Monitor Group (now Monitor Deloitte), where he led over 20 strategy projects with an eye to uncovering new growth opportunities for clients.

Miron is an alumnus of the University of Toronto (PhD in neuroscience), University of Massachusetts (MBA) and the Harvard Business School (Executive Education in Disruptive Innovation and Strategic Agility).